Abcam, ab316017, Anti-Aldose reductase antibody [EPR28780-7] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Aldose reductase antibody. Carrier free. Suitable for Dot, WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Recombinant full length protein - Human, Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28780-7,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:Dot, Flow Cyt (Intra), ICC/IF, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab316017 is the carrier-free version of
ab316016
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Aldose reductase also known as AR or ALR2 is an important enzyme in the polyol pathway. It has a molecular mass of about 36 kDa and reduces aldehydes including glucose to their corresponding alcohols. Aldose reductase is expressed widely in various tissues such as kidney lens and retina. The enzyme uses NADPH as a cofactor which is important for its catalytic activity.
Biological function summary
The main function of aldose reductase involves converting glucose to sorbitol a process particularly active under hyperglycemic conditions. It does not form a part of a larger complex but works individually to facilitate this conversion. Sorbitol the product of its enzymatic reaction eventually converts to fructose through the action of sorbitol dehydrogenase. This two-step conversion can contribute to cellular damage due to osmotic stress when sorbitol accumulates.
Pathways
Aldose reductase plays a central role in the polyol pathway. This pathway becomes highly relevant when blood glucose levels are elevated. During such conditions aldose reductase activity increases to convert excess glucose to sorbitol. This activity links it to other proteins like sorbitol dehydrogenase which completes the conversion to fructose.
Aldose reductase has strong connections to diabetic complications specifically diabetic neuropathy and retinopathy. The enzyme’s increased activity under high glucose conditions can lead to osmotic stress and tissue damage. Interactions with other proteins in the metabolic shift associated with diabetes such as sorbitol dehydrogenase underline its involvement. Aldose reductase inhibitors show potential in mitigating these adverse effects by reducing sorbitol accumulation.